G6PD Deficiency Association: Free Mobile App
In early June 2015 the Association has released a free Mobile App for iOS (iPad and iPhone) and Android (most other mobile devices) operations systems.
The App is offered in both English and Italian to all donors and healthcare professionals registered on our Web site (registration is free).
The App main feature is the Contraindicated Drugs SEARCH, where you can enter a drug name (e.g., Dopamine) or a trade name (e.g., Levadopa) and view results that include:
- Drug name
- Risk level
- Molecular formula
- All trade names of this drug (covering many world countries) [tap on previous screen to view].
All data has been created, updated and is constantly being updated by a group of pharmaceutical experts, so it can be trusted.
- CONTRAINDICATED DRUGS: list that includes drug names, molecular formula, risk level
- TRADE NAMES: List of drug trade names alongside country where each is sold.
- SETTINGS: Where you can select a language and view a Disclaimer.
You'll be required to enable the App upon first use. Eligible users are sent a message that includes the required credentials (user-name and password). If you have not received this message, please contact us using this link.
Links for download:
You may find other apps (for pay) offering information regarding G6PD Deficiency, some of them even citing our Web site as source (without asking our permission and thus in breach of copyright laws). Please note that most information offered by the apps we've examined was copied from an older version of our Web site, listing unverified lists of contraindicated drugs (many years-old, before we hired qualified pharmaceutical experts to verify and update our lists). Use these apps with due caution.
Since this is the first version of the Mobile App, we'll be more than happy to hear your impressions and suggestions. Please send us your feed back here.
PLEASE NOTE: The App is offered FREE OF CHARGE to donors and healthcare professionals . Donations may be made here from as little as $5.00.